ROCKVILLE, Md. & MONTREAL--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
